Dodge Slagle, DO
Psychiatry · Henderson, NVNPI 1578570578
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,891 of the $27,063 with a category attached, or 84.6%. Teva Pharmaceuticals USA, Inc. accounts for 82.0% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $20,195 and has fallen 99.4% since, to $122 in 2025. Among psychiatry clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $218.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$22K
- Neurocrine Biosciences, Inc.$3K
- AbbVie$481
- Otsuka America Pharmaceutical, Inc.$306
- Takeda Pharmaceuticals U.S.A., Inc.$163
- Jazz Pharmaceuticals Inc.$159
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$22,89185%
- Travel & lodging$9494%
- Food & beverage$3,22312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 28 | $22,178 |
| Neurocrine Biosciences, Inc. | 9 | $2,724 |
| AbbVie(2 entities) | 21 | $481 |
| Otsuka America Pharmaceutical, Inc. | 11 | $306 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $163 |
| Jazz Pharmaceuticals Inc. | 3 | $159 |
| Bioxcel Therapeutics, Inc. | 2 | $124 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Alkermes, Inc. | 5 | $112 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $111 |
| Vanda Pharmaceuticals Inc. | 4 | $103 |
| Lundbeck LLC | 5 | $83 |
| Brainsway USA Inc | 2 | $82 |
| Johnson & Johnson | 4 | $65 |
| Eisai Inc. | 2 | $51 |
| Neuronetics, Inc. | 2 | $48 |
| Acadia Pharmaceuticals Inc | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Almatica Pharma LLC | 2 | $29 |
| Merck | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,063 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 31 | $35,458 |
| Quetiapine Fumarate | 99 | $2,086 |
| BelsomraSuvorexant | 11 | $2,039 |
| Lamotrigine | 119 | $1,482 |
| Clonazepam | 124 | $1,168 |
| Mirtazapine | 87 | $1,070 |
| Lurasidone Hcl | 17 | $1,022 |
| Buspirone Hcl | 68 | $1,007 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 29 | $941 |
| Duloxetine Hcl | 31 | $875 |
| Bupropion XlBupropion Hcl | 48 | $754 |
| Fluvoxamine Maleate | 18 | $735 |
| Trazodone Hcl | 44 | $670 |
| Aripiprazole | 35 | $595 |
| Olanzapine | 23 | $579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $306 | $35,45831 claims |
| MerckBelsomra | $19 | $2,03911 claims |
| Almatica Pharma LLCSertraline Hcl | $29 | $53661 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Henderson
- Mitchell GalerkinHenderson$23K
- Josil GeorgeHenderson$3K
- Jonathan StillHenderson$3K
- Mark SuhanyHenderson$2K
- Leo GallofinHenderson$2K
- Jelena KunovacLas Vegas$1.2M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Aaron RitterLas Vegas$173K
- Mustafa RawafLas Vegas$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.